This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Under Kappos’s leadership, the office embraced a more applicant-friendly approach, focusing on working with inventors to achieve allowable claims rather than pursuing multiple rounds of rejection. Continue reading this post on Patently-O. More recent data points to subtle but noteworthy changes in USPTO practice.
On September 22, 2022, the U.S. Patent and Trademark Office (USPTO) directed patent practitioners to current case law and sections of the Manual of Patent Examining Procedure (MPEP) as reminders as the patent practitioners continue to work in the Artificial Intelligence (AI) technology space. In In re Appl.
On September 22, 2022, the U.S. Patent and Trademark Office (USPTO) conducted a live meeting for its Artificial Intelligence (AI) and Emerging Technologies (ET) Partnership Series. In this chart, Mr. Pairolero analyzed patentapplication filings in accordance with the country of the patent owner once the patentapplication granted.
FDA in December 2022 and holds promise not only for treatment but also for prevention through its twice-yearly injections. The looming threat is the pending patentapplications by Gilead in India. Below is a table summarising the major patentapplication statuses for Lenacapavir by Gilead Sciences Inc.
Rules amending the Patent Rules1 were registered on June 2, 2022 and will largely come into force on October 3, 2022. The rules introduce claim fees and a continued examination scheme to Canadian patent practice and are similar to draft rules published for public comment in 2021 and discussed in our previous article.
We’re pleased to bring to you a 2 part guest post by Amit Tailor on the question of when a patentapplication can be divided, that came up in the recent case of Boehringer Ingelheim vs. The Controller. When can/not a PatentApplication be Divided? Permanent Address of the Pen of K?cab?). Author: Amit Tailor.
OpenAI's prototype of ChatGPT, released at the end of November 2022, drew rapid, widespread public attention for its ability to provide articulate, human-like responses across a wide variety of knowledge domains.
The China National Intellectual Property Administration (CNIPA) released a draft of new measures that would downgrade the ratings of Chinese patent agencies that approve abnormal or fraudulent patents. CNIPA released the draft on October 8, which expands on a trial started in January 2022 in four provinces.
January 2022 Federal Circuit Newsletter (Japanese) January 2022 Federal Circuit Newsletter (Chinese) Silence May Support Negative Claim Limitation In Novartis Pharmaceuticals v. Accord Healthcare Inc.
2021-2022 was a big year for the Osgoode’s mooting team entry for the USPTO National PatentApplication Drafting Competition. We invite you to participate in the tryouts for the 2022-2023 National PatentApplication Drafting Competition ! About the National PatentApplication Drafting Competition.
The 2024 Indicator focuses on the developments from 2023 and compares it with the figures from 2022. As the name suggests, the report features facts and figures about different types of IPRs, but this post is limited to the numbers on Patents, specifically focusing on data about the Indian patent regime. million filings (i.e.
C)-IPD 5/2022 and W.P.(C)-IPD C)-IPD 6/2022, the Petitioner (European Union) filed two writ petitions against two orders passed by the Controller General of Patents for deemed abandonment of its patentapplications. In the recent case of The European Union vs. Union of India and Ors.,
Image with text reading “Keep Calm and Expect Delays” Last week, the Delhi High Court pronounced a decision rebuking a patentapplicant for causing unnecessary delays in the patentapplication process by seeking repeated adjournments and not filing written submissions on time. In the case of FMC Corporation v.
We’re pleased to bring to our readers a 2 part post by Amit Tailor on the recent case Nippon A&L vs The Controller of Patents, which looked into questions of how and to what extent a claim in a patentapplication can be amended under the Patents Act. vs. THE CONTROLLER OF PATENTS [ C.A.(COMM.IPD-PAT)
We invite you to participate in the tryouts for the annual PatentApplication Drafting Competition (PADC)! The winner of each regional round will compete in the National Finals held at the United States Patent and Trademark Office (USPTO) headquarters in Alexandria, Virginia. .
This is a reminder that submissions to try out for the annual National PatentApplication Drafting Competition (PDC) team are due on Friday, October 22 at 3pm ! The winner of each regional round will compete in the National Finals held at the United States Patent and Trademark Office (USPTO) headquarters in Alexandria, Virginia. .
On September 22, 2022, the U.S. Patent and Trademark Office (USPTO) directed patent practitioners to current case law and sections of the Manual of Patent Examining Procedure (MPEP) as reminders as the patent practitioners continue to work in the Artificial Intelligence (AI) technology space. In In re Appl.
patentapplications reached an all-time high in 2022, IBM Corp. fell from its decadeslong position atop the list of companies securing the most granted patents and was replaced by Samsung, according to a report released Tuesday. Although the number of U.S.
Delhi High Court on Non-filing of Written Submission to Delay PatentApplication Process. The Controller of Patents where it rebuked the Plaintiff for not filing written submissions in time and thereby delaying the patentapplication process. on 2 November, 2022 (Delhi High Court) . Image from here.
by Dennis Crouch In a significant decision, the Federal Circuit has established a more rigorous test for determining when a published patentapplication claiming priority to a provisional application can be considered prior art as of its provisional filing date. 2022-1945 (Fed. In re Riggs , Case No.
companies and inventors still filed more patentapplications with the European Patent Office (EPO) than any other country, according to its Patent Index 2022, which was released today. patentapplications numbered 48,088, a 2.9% The index showed that U.S. increase from 2021.
USPTO Proposes Electronic Issuance of Patents - In a notice of proposed rulemaking published last month in the Federal Register (86 Fed. Patent and Trademark Office is proposing to issue patents electronically through its patent document viewing systems (i.e., 71209), the U.S.
The increasing presence of data-driven solutions in the healthcare and life sciences sector is apparent from the rise in numbers of patents and patentapplications. The number of published bioinformatics patents and patentapplications in the last decade has nearly doubled. By: MoFo Life Sciences
Patent and Trademark Office (USPTO) today announced the findings of two reports conducted by third-party academic economists and submitted to Congress late last year, as required by the Unleashing American Innovators Act of 2022 (UAIA).
2022-1945 (Fed. 24, 2025) Our Case of the Week explores the power of an examiner to request a rehearing after the Board has entered a decision on an application. In re: Riggs, Appeal No.
On January 6, 2022, the U.S. Patent and Trademark Office (USPTO) announced a Deferred Subject Matter Eligibility Response Pilot Program (the “DSMER Program”). Currently, the USPTO applies a “compact prosecution approach” in examining patentapplications. Introduction. We provide a brief overview of this program.
The EPO has released the draft Guidelines for Examination 2022. The new Guidelines will come into force on 1 March 2022. However, it is now clear that the 2022 Guidelines will do little to ameliorate the requirements introduced in 2021. The deadline for submitting a response to the consultation is 15 April 2022.
Key Takeaways - To support the CHIPS Act of 2022, the USPTO initiated a pilot program that provides expedited examination of certain patentapplications directed to manufacturing semiconductor devices, potentially reducing the time to patent issuance by between one and two years.
The Federal Circuit continues to tighten the standards for written description of functional claims, particularly in the biologics realm, which is putting patentapplicants in the position of having to pursue narrow claims directed to specific sequences.
New approach to description amendments By way of a brief recap, the recent controversy over description amendments began with a significant tightening in the 2021 EPO Guidelines for Examination of the requirement for applicants to amend the description of a patentapplication in line with the allowed claims ( IPKat ).
Life sciences patentapplications often contain DNA, RNA, and amino acid sequences in the specification, claims, or figures that are required to be provided in the form of a sequence listing.
On September 22, 2022, the U.S. Patent and Trademark Office (USPTO) conducted a live meeting for its Artificial Intelligence (AI) and Emerging Technologies (ET) Partnership Series. In this chart, Mr. Pairolero analyzed patentapplication filings in accordance with the country of the patent owner once the patentapplication granted.
Killian is involved in an ongoing patent dispute in which the Patent Trial and Appeal Board (PTAB) rejected claims of his U.S. PatentApplication No. Court of Appeals for the Federal Circuit (CAFC) affirmed the ruling in August 2022. 14/450,042 under Section 101. In the petition, Killian claims that the U.S.
PatentApplication 15/131,442 (the “’442 Patent”) with claims directed to a method of increasing prostacyclin release in systemic blood vessels of a human to improve vasodilation and reduce hypertension. Background John L. Couvaras filed U.S.
On April 13, 2022, the Federal Court of Australia, on appeal, reversed its 2021 decision that DABUS, an artificial intelligence (AI) machine, qualified as an inventor for a patentapplication under Australian law. Thaler has filed patentapplications in several countries around the world for inventions created by DABUS.
2022-1756 (Fed. The district court had ruled against the patentee (IBM) — finding one patent ineligible and the other not infringed. by Dennis Crouch The Federal Circuit handed down a mixed decision in Chewy, Inc. International Business Machines Corp. 5, 2024) ChewyvIBM.
Germany’s Federal Patent Court has set aside a decision by the country’s Patent and Trademark Office (DPMA) that refused a patentapplication naming an artificial intelligence (AI) as the inventor. The application was filed on October 17, 2019, and is titled “Food Container”.
This week, patent data analytics firm IFI CLAIMS published its annual report of the top 50 U.S. patent recipients and the global 250 largest patent portfolios for 2022. The list provides a comprehensive snapshot of the patent landscape with insights into growing trends in the industry.
A similar account of inevitable human innovation is also discussed in the World Intellectual Property Report 2022 (“ Report ”) titled as “ The Direction of Innovation ”, very recently published by the World Intellectual Property Organization (“ WIPO ”). In this era, 7% of all patents were from the medical innovation sector.
On August 5, 2022, in Thaler v. 5, 2022), the Federal Circuit held that an artificial intelligence (“AI”) system cannot be listed as an inventor on a United States patent. 21-2347 (Fed.
IPKat has also sifted through the 100s of Boards of Appeal decisions published in 2022, to bring you the most eye-catching and relevant to ongoing EPO practice. T 0471/20) (5 Jan 2022) Changes in the draft 2022 EPO Guidelines for Examination on description amendments: Substantial changes or window-dressing? (7
The America Invents Act became law in September 2011, but the first-to-invent provisions only took effect for patentapplications filed after March 16, 2013. For the chart below, I pulled up records from US patentapplication publications from the past 10 years and looked at whether the applicant claimed pre-AIA or post-AIA status.
Last week, the USPTO released its 2022‒2026 Strategic Plan. How are these initiatives likely to affect patentapplicants and owners? The Strategic Plan outlines the USPTO’s overarching goals for the coming years. By: MoFo Life Sciences
We organize all of the trending information in your field so you don't have to. Join 9,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content